DEXCOM INC — Director's Dealing 2017

Feb 14, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2017-02-10

Reporting Person: Balo Andrew K (EVP, Clinical and Regulatory)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-02-10	Common Stock	M	727	$9.8	Acquired	107072	Direct
2017-02-10	Common Stock	S	727	$79.3	Disposed	106345	Direct
2017-02-10	Common Stock	S	2473	$79.3	Disposed	103872	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-02-10	Incentive Stock Option (right to buy)	$9.8	M	727	Disposed	2020-03-12	Common Stock (727)	Direct

Footnotes

F1: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2: Included in this number are 70,084 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 23,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 8,334 of which were granted on March 8, 2014 and shall vest through March 8, 2017.